Loading...

Jasper Therapeutics, Inc.

JSPRWNASDAQ
Healthcare
Biotechnology
$0.12
$0.00(0.00%)

Jasper Therapeutics, Inc. (JSPRW) Stock Overview

Explore Jasper Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 63.7/100

Key Financials

Market Cap1.9M
P/E Ratio5.94
EPS (TTM)$-3.84
ROE0.19%
Fundamental Analysis

AI Price Forecasts

1 Week$0.11
1 Month$0.09
3 Months$0.00
1 Year Target$0.02

JSPRW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Jasper Therapeutics, Inc. (JSPRW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.02.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 5.94 and a market capitalization of 1.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
0.00%
Profit Growth
$0.94
100.00%
EPS Growth
$0.94
20.87%
Operating Margin
-7067.21%
10.71%
ROE
19.07%
100.00%
Dividend Yield
0.00%
Analyst Recommendations data is not available for JSPRWAnalyst Recommendations details for JSPRW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

CEO

Ronald A. Martell

Employees

64

Headquarters

2200 Bridge Pkwy, Redwood City, DE

Founded

1970

Frequently Asked Questions

;